← 返回前沿论文

单细胞追踪揭示黑色素瘤 TIL 治疗过程中肿瘤反应性 T 细胞的可塑性

英文原题:Single-cell tracking reveals tumor-reactive T cell plasticity during melanoma TIL therapy.

PubMed 2026/09/15(内容时间) Cell Rep Med Q1 · IF 14(JCR 2025)

研究概要

TIL(肿瘤浸润淋巴细胞)过继细胞治疗可在转移性黑色素瘤中诱导持久缓解,然而在体外扩增过程中及回输后,调控肿瘤反应性T细胞命运的克隆和转录动态仍知之甚少。

中文摘要

TIL(肿瘤浸润淋巴细胞)过继细胞治疗可在转移性黑色素瘤中诱导持久缓解,但调控肿瘤反应性T细胞命运在体外扩增期间及回输后的克隆和转录动态仍知之甚少。在此,我们对7例黑色素瘤患者的五个时间点进行了纵向单细胞RNA和T细胞受体测序,涵盖基线肿瘤、两阶段体外扩增以及输注后血液和肿瘤活检,并解析了CD8+和CD4+两个区室。肿瘤反应性CD8+ T细胞从耗竭状态中被重新激活,并获得HLA-II高表达或KLF2高表达谱。我们进一步深入剖析了肿瘤反应性CD4+区室,揭示了谱系依赖性的重新激活,其中滤泡辅助T细胞采用效应状态,而耗竭的CD4+ T细胞则保留功能障碍。在三个队列的无应答者中,共转移的17型T细胞以及转移后新出现的调节性T细胞扩增与治疗失败相关。这些数据定义了跨越两个谱系的亚型特异性特征,以指导TIL扩增。

展开英文摘要原文

Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) induces durable responses in metastatic melanoma, yet the clonal and transcriptional dynamics governing tumor-reactive T cell fate during ex vivo expansion and after transfer remain poorly understood. Here, we perform longitudinal single-cell RNA and T cell receptor sequencing across five time points, from baseline tumors through two-phase ex vivo expansion to post-infusion blood and tumor biopsies, in seven melanoma patients, resolving both the CD8 + and CD4 + compartments. Tumor-reactive CD8 + T cells are reinvigorated from exhaustion and acquire HLA-II-high or KLF2-high profiles. We further dissect the tumor-responsive CD4 + compartment in depth, revealing lineage-dependent reinvigoration in which follicular helper T cells adopt an effector state while exhausted CD4 + T cells retain dysfunction. In non-responders, across three cohorts, co-transferred type 17 T cells and de novo regulatory T cell expansion after transfer associate with treatment failure. These data define subtype-specific signatures across both lineages to guide TIL expansion.

论文信息

作者
Sandholzer MT、Serger C、Liner AG、Uzun S、König D、Thut H、Ritschard R、Fürst JD
第一作者单位
Department of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland. Electronic address: michael.sandholzer@unibas.ch.Switzerland
通讯作者单位
Department of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland; Division of Medical Oncology, University Hospital Basel, Basel, Switzerland; Innovation Focus Cell Therapies, University Hospital Basel, Basel, Switzerland. Electronic address: heinz.laeubli@unibas.ch.Switzerland
期刊
Cell reports. Medicine2026 Sep 15
原文标识
PubMed 42743921 · DOI 10.1016/j.xcrm.2026.103051